Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
AstraZenenca
Astellas Pharmaceuticals
Salix Pharmaceuticals Ltd
GlaxoSmithKline
Actavis
Pfizer
...
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs for each application, including
Hospitals
Clinics
Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Preface Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Eluxadoline Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 Alosetron Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Rifaximin Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Loperamide Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.6 Diphenoxylate + Atropine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.7 Dicyclomine and Hyoscyamine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Type
8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Application (Consumption and Market Share)
8.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Application (Consumption and Market Share)
8.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Application (Consumption and Market Share)
8.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 AstraZenenca
9.1.1 AstraZenenca Profiles
9.1.2 AstraZenenca Product Portfolio
9.1.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.1.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
9.2 Astellas Pharmaceuticals
9.2.1 Astellas Pharmaceuticals Profiles
9.2.2 Astellas Pharmaceuticals Product Portfolio
9.2.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.2.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
9.3 Salix Pharmaceuticals Ltd
9.3.1 Salix Pharmaceuticals Ltd Profiles
9.3.2 Salix Pharmaceuticals Ltd Product Portfolio
9.3.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.3.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
9.4 GlaxoSmithKline
9.4.1 GlaxoSmithKline Profiles
9.4.2 GlaxoSmithKline Product Portfolio
9.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
9.5 Actavis
9.5.1 Actavis Profiles
9.5.2 Actavis Product Portfolio
9.5.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.5.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
9.6 Pfizer
9.6.1 Pfizer Profiles
9.6.2 Pfizer Product Portfolio
9.6.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
9.6.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
10 World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Players
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Players 2014-2020
10.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Assessment of Players 2014-2020
11.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Assessment of Players 2014-2020
11.1.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Assessment of Players 2014-2020
11.1.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Assessment of Players 2014-2020
11.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Assessment of Players 2014-2020
11.2.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Assessment of Players 2014-2020
11.4.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Assessment of Players 2014-2020
11.4.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Assessment of Players 2014-2020
11.4.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries/Regions 2014-2020
12.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries/Regions 2014-2020
12.2.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries/Regions 2014-2020
12.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries/Regions 2014-2020
12.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries/Regions 2014-2020
12.4.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries/Regions 2014-2020
12.4.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales & Revenue Forecast 2021-2026
14.1 World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales and Market Share by Regions
14.1.2 World Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsRevenue and Market Share by Regions
15 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Preface
15.1.2 Eluxadoline
15.1.3 Alosetron
15.1.4 Rifaximin
15.1.5 Loperamide
15.1.6 Diphenoxylate + Atropine
15.1.7 Dicyclomine and Hyoscyamine
15.2 Consumption Forecast by Application, 2021-2026
16 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Preface
16.1.2 Eluxadoline
16.1.3 Alosetron
16.1.4 Rifaximin
16.1.5 Loperamide
16.1.6 Diphenoxylate + Atropine
16.1.7 Dicyclomine and Hyoscyamine
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Preface
17.1.2 Eluxadoline
17.1.3 Alosetron
17.1.4 Rifaximin
17.1.5 Loperamide
17.1.6 Diphenoxylate + Atropine
17.1.7 Dicyclomine and Hyoscyamine
17.2 Consumption Forecast by Application, 2021-2026
18 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Preface
18.1.2 Eluxadoline
18.1.3 Alosetron
18.1.4 Rifaximin
18.1.5 Loperamide
18.1.6 Diphenoxylate + Atropine
18.1.7 Dicyclomine and Hyoscyamine
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Preface
19.1.2 Eluxadoline
19.1.3 Alosetron
19.1.4 Rifaximin
19.1.5 Loperamide
19.1.6 Diphenoxylate + Atropine
19.1.7 Dicyclomine and Hyoscyamine
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) Trend 2021-2026
20.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Profit Trend 2021-2026
21 Conclusion